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Abstract
Background: Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor
outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the
difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the
prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs).
Methods: Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers
into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR).
Results: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/
or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the
clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better
prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After
multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the
patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about
6~8% of breast cancers in publicly available breast cancer datasets
Conclusion: The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this
result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of
subgroups of patients for therapeutic classification.
Background
Breast cancer is a heterogeneous disease, and basal-like
breast cancers (BLBCs) have attracted particular attention
because they have been shown to have shorter survival
compared to the other subtypes [1,2]. With the practical
difficulties of gene-expression profiling as a routine diag-
nostic tool, immunohistochemical surrogate panels have
been introduced to identify BLBCs that are ‘triple-negative
breast cancers’ (TNBCs) (estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, HER2 not overex-
pressed) [2,3]. The immunohistochemical panel that is
considered to be the gold standard in the identification of
BLBCs was proposed by Nielsen et al., in which BLBCs are
defined as breast cancers expressing neither ER/PR nor
HER2 and expressing CK5/6 and/or EGFR [2]. Both
TNBCs and BLBCs have attracted clinical interest in
regard to their prognoses and associated therapeutic
approaches [4]. Several clinical trials have been conducted
on the routine diagnostic immunohistochemical assay of
TNBCs [5]. However, it should be noted that identification
of a subgroup of tumors based solely on the lack of
expression of immunohistochemical markers affords the
risk of incorrect assignment due to technical artifacts [6].
Recently, Kreike et al. examined the gene expression
and pathological characteristics of 97 TNBCs and con-
cluded that “BL tumors can be reliably defined by TN
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synonymous with BL tumors” [7]. However, Rakha et al.
mentioned that equating TNBC with BLBC is mislead-
ing, and insisted that while most TNBCs fall into the BL
molecular subtype of breast cancer, the terms are not
completely synonymous [8]. Many studies have shown
that TNBCs have the worst prognosis without the
option of chemotherapy. On the other hand, other stu-
dies have shown that the expression of “basal markers”
(CK5/6, CK14, CK17, and/or EGFR) is associated with a
poor prognosis [9-11]. Significantly, Rakha et al. and
Cheang et al. reported that BLBCs defined by five bio-
markers showed worse response to chemotherapy, and
shorter survival [12,13].
Therefore, the aim of our study was to compare prog-
nosis between models in which breast cancers were
divided by four subtypes (including TNBC) and five sub-
types (including BLBC), and to define the associated clini-
copathological factors. To perform this study, we designed
a longitudinal study, and used immunohistochemical mar-
kers to identify breast tumor intrinsic subtypes using for-
malin-fixed, paraffin-embedded (FFPE) tumor blocks, and
examined the clinicopathologic parameters of BLBCs and
TNBCs. Also, we explored BLBC and TNBC in two large
microarray datasets by comparing the expression levels of
the five markers according to the subtypes.
Methods
Study population
We collected breast cancer cases from the Samsung Medi-
cal Center in Seoul, Korea. Inclusion criteria for this study
were: 1) histologically verified incident breast cancer; 2)
female; 3) between 20-80 years of age; 4) enrolled between
January 1, 1995 and December 31, 2002; 5) breast tissue
samples available for study. All of the subjects were diag-
nosed stage I to III primary breast cancer and underwent
surgical treatment and adjuvant chemotherapy according
to standard treatment protocols. Radiation therapy was
performed in the cases of breast conserving surgery or on
patients with stage III breast cancer. All ER-positive
patients underwent hormonal therapy with tamoxifen. No
patients underwent anti-HER-2 therapy. We reviewed each
patient’s medical record for clinical information, including
follow-up status and outcome information. Breast cancer
stage was classified according to the American Joint Com-
mittee on Cancer (AJCC) TNM criteria (6th edition). In
the case of live subjects, the last date of follow-up was June
30, 2007. The protocol for the study was approved by the
institutional review board (IRB) of the Samsung Medical
Center.
Immunohistochemistry and fluorescent in situ hybridization
The original H&E-stained slides from the patients in the
retrospective cohort were reviewed, and representative
tumor regions without secondary change, such as
hemorrhage, necrosis, and fibrosis, were marked by a
pathologist (YL Choi). Corresponding 1290 FFPE breast
cancer tissue blocks were obtained. Two 2 mm cores
from each case were obtained, and two sets of tissue
microarray (TMA) paraffin blocks were made. The sec-
tions were deparaffinized with xylene, hydrated in serial
dilutions of alcohol, and then immersed in 3% hydrogen
peroxide solution to neutralize endogenous peroxidase
activity. Next, sections were microwaved in citrate buffer
for antigen retrieval. Slides were incubated with mono-
clonal antibodies against CK5/6 (1:100, M7237, DAKO,
Carpinteria, CA, USA), HER2 (1:250, A0485, DAKO),
and EGFR (1:30, M7239, Novocastra) for 1 hour at
room temperature. After washing, the tissue section was
reacted with the biotinylated anti-mouse secondary anti-
body, followed by incubation with streptavidin-horserad-
ish-peroxidase complex. Slides were washed, and the
chromogen was developed for 5 minutes with liquid
3,3’-diaminbenzidine (DAKO). HER2 fluorescent in situ
hybridization assay was performed with the PathVysion
HER2 DNA Probe Kit (Abbott Molecular, Inc.) accord-
ing to the manufacturer’s instructions. The average copy
number for each probe was determined and the amplifi-
cation ratio was calculated as a ratio between the aver-
age copy per cell for HER2 and the average copy
number for centromere 17.
Two pathologists (YL Choi, JS Choi) were blinded to
the clinical outcomes of the patients, and independently
scored the results of the staining. ER and PR stain data
were acquired from the pathologic report. The staining
studies were scored using the Allred score (AS), a
method that semi-quantitates the proportion of positive
cells (scored on a 0 to 5 scale) and staining intensity
(scored on a 0 to 3 scale), with a maximum score of 8;
an AS > 2 was considered positive [14]. The CK5/6,
EGFR and HER2 immunohistochemical results were
from TMA and considered positive with the following
criteria in at least one core. CK5/6 stains were consid-
ered positive if any cytoplasmic and/or membranal
staining was observed. Immunostaining for EGFR was
interpreted as positive when at least 10% of the tumor
cells showed moderate to strong membranal staining
[15]. HER2 positivity was defined as an intensity of 3+
by IHC or as gene amplification ratio of ≥ 2.0 by FISH
in the case of an intensity of 1+ or 2+ by IHC [16].
Definition of breast cancer subtypes by
immunohistochemistry
The immunohistochemical surrogate panel (ER, PR,
HER2, EGFR, and CK5/6) used to define the breast can-
cer subtypes has been previously published [2,17]. In
this study, we used two subtyping schemes. Each case
was classified as one of five IHC-based subtypes: luminal
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Page 2 of 15A (ER+ and/or PR+, HER2−), luminal B (ER+ and/or
PR+, HER2+), HER2 (ER−,P R −,a n dH E R 2 + ) ,a n d
TNBC (ER-, PR-, and HER2-) [17]. TNBCs were further
divided into BLBCs and QNBC/5NPs according to the
basal-markers. TNBC expressing either EGFR or CK5/6
was defined as BLBC (ER−,P R −,H E R 2 −,C K 5 / 6 + ,a n d /
or EGFR+). Breast tumors which were TN and
expressed neither CK5/6 nor EGFR were defined as
‘quintuple-negative breast cancer’ (QNBC/5NP) (ER−,
PR−, HER2−, CK5/6−, and EGFR−).
Statistical Analysis
Disease free survival (DFS) was defined as the time
from the date of diagnosis to the date of the documen-
tation of relapse, including locoregional recurrence
and/or distant metastasis. Overall survival (OS) was
expressed as the number of months from diagnosis to
the date of death. Differences in the frequencies of
basic characteristics, clinical parameters, and subtypes
were statistically analyzed using the chi-square test, or
Fisher’s exact test in the case of less than five expected
cases. For multiple statistical comparisons, chi-square
test was corrected by Bonferroni’s correction. Survival
curves were constructed using the Kaplan-Meier
method, and the log-rank test was used to compare
mean survival rates across subtypes. For multivariate
analysis, Cox regression models were built to estimate
the adjusted hazard ratios (HRs) of breast cancer sub-
types with tumor size, lymph node involvement and
adjuvant chemotherapy. To test the statistical signifi-
cance between model 1 (5-subgrouping) and model 2
(4-subgrouping), a likelihood ratio test of the differ-
ences was used. The null hypothesis was that the
model 2 did not predict survival differently than model
1. Statistical significance was defined as P < 0.05. All
statistical analyses were performed using SPSS 15.0
and SAS 9.1 statistical software packages.
Microarray Analysis
We classified TNBC into BLBC and QNBC/5NP with
two public independent gene expression datasets,
Vijver et al.(316 samples) and Wang et al.(286 sam-
ples) [18-20] Vijver et al. was generated with 2-color
oligo chips (Agilent, Hu25K) and Wang et al. was 1-
color oligo chips (Affymetrix, U133X3P). Each dataset
consists of a large number of random breast cancer
patients. Vijver et al. is available at http://www.rii.com/
publications/2002/nejm.html, and Wang et al. can be
downloaded from the NCBI GEO data repository
(GSE2034). For Wang et al, gene expression values
were centered by subtracting the mean value of each
probe set across the samples from each measured
value. Both datasets included only ER IHC informa-
tion, so the other four IHC results (PR, HER2, CK5/6
and EGFR) were dichotomized into ‘positive (+)’ and
‘negative (-)’ by the mRNA expression levels of the
corresponding genes on the microarray chips. Under
the assumption that Cheang et al.’s cohort with 4,046
breast samples was representative of a random sample
of breast cancer population and the proportion of ER
IHC result (ER+: 70.5%) was similar to the ER IHC
results (Vijver et al.: 76%, Wang et al.: 72%) in the
selected microarray data sets, we used the proportion
of the status of the IHC results of each marker in his
dataset to determine the cut-off for the surrogate
mRNA expression for the selected microarray datasets
[13]. For instance, the cut-off for KRT5 which corre-
sponds to CK5/6 was determined at the point where
the proportion of ‘+’ to ‘-’ was the same as the propor-
tion of ‘CK5/6 +’ to ‘CK5/6-’ in Cheang et al.’sI H C
results (Additional File 1, Figure S1). The cut-offs for
PGR, KRT5 and EGFR were determined by synchroniz-
ing the proportion of their statuses in Cheang et al.’s
IHC results and in each microarray dataset (Additional
File 1, Figure S1). The cut-off for ERBB2 was deter-
mined from the clear bimodal distribution, by assign-
ing ‘+’ for right side and ‘-’ for left side (Additional
File 1, Figure S1). The only available IHC result, ER,
was not replaced by the expression of ESR1. Each sam-
ple from the microarray datasets was assigned to one
of the five subtypes according to the status of the five
markers.
Results
Patients Characteristics
After excluding 339 (26.3% (339/1290)) cases due to fail-
ure of staining, 951 cases that had informative immuno-
histochemical results were included in the study. The
median age in the study population at diagnosis was 47
years (range, 20-80 years). The clinicopathologic charac-
teristics of patients are summarized in Table 1. Ductal
histology was the most prevalent breast cancer type, and
was present in 91.6% (872/951). Lobular histology was
present in 2.7% (26/951). The remaining 5.7% (53/951)
had cancers of other histological types, including muci-
nous, tubular, medullary, and metaplastic types. Mas-
tectomy was performed in 62.3% (592/951), and 37.7%
(359/951) underwent breast conserving surgery. Out of
the 951 patients, 83.7% (796/951) received adjuvant che-
motherapy; 491 were treated with nonanthracycline-
based chemotherapy - CMF (cyclophosphamide, metho-
trexate, 5-fluorouracil) and 194 were treated with
anthracycline-based chemotherapy - AC (doxorubicin,
cyclophosphamide) and FAC (5-fluorouracil, doxorubi-
cin, cyclophosphamide). Remaining 155 patients (16.3%
(155/951)) did not receive any adjuvant systemic che-
motherapy. The median follow-up time was 75.0 months
(from 2.47 to 152.1 months).
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Page 3 of 15Table 1 Clinicopathologic characteristics of breast cancer subtypes
Molecular Subtyping
All Five subtypes Four
subtypes
P value between
five subtypes *,†
P value between
four
subtypes **,†
Variables IHC-
Luminal
A
IHC-
Luminal
B
IHC-HER2 IHC-BLBC IHC-
QNBC/
5NP
IHC-TNBC
N = 951 N = 486
51.1%
N = 123
12.9%
N = 113
11.9%
N = 139
14.6%
N=9 0
9.5%
N = 229
24.1%
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Age Group (years) < 0.001 < 0.001
> 50 590 62.0 297 61.1 87 70.7 51 45.1 97 69.8 58 64.4 155 67.7
≥ 50 361 38.0 189 38.9 36 29.3 62 54.9 42 30.2 32 35.6 74 32.3
Family history of
breast cancer
0.006 0.086
No 916 96.3 470 96.7 121 98.4 111 98.2 126 90.6 88 97.8 214 93.4
Yes 35 3.7 16 3.3 2 1.6 2 1.8 13 9.4 2 2.2 15 6.6
Tumor Size 0.014 0.006
≤ 2 cm 392 41.2 228 46.9 39 31.7 35 31.0 52 37.4 38 42.2 90 39.3
2-5 cm 493 51.8 231 47.5 75 61.0 64 56.6 76 54.7 47 52.2 123 53.7
> 5 cm 66 6.9 27 5.6 9 7.3 14 12.4 11 7.9 5 5.6 16 7.0
N Staging 0.178 0.014
N0 498 52.4 246 50.6 52 42.3 63 55.8 89 64.0 48 53.3 137 59.8
N1 247 25.9 131 27.0 40 32.5 22 19.5 31 22.3 23 25.6 54 23.6
N2 118 12.4 64 13.2 19 15.4 13 11.5 12 8.6 10 11.1 22 9.6
N3 88 9.2 45 9.3 12 9.8 15 13.3 7 5.0 9 10.0 16 7.0
AJCC stage 0.014 0.008
I 254 26.7 148 30.5 19 15.4 22 19.5 38 27.3 27 30.0 65 28.4
II 467 49.1 221 45.5 69 56.1 57 5.04 78 56.1 42 46.7 120 52.4
III 230 24.2 117 24.1 35 28.5 34 30.1 23 16.5 21 23.3 44 19.2
LN involvement 0.016 0.020
Negative 498 52.4 246 50.6 52 42.3 63 55.8 89 64.0 48 53.3 137 59.8
Positive 453 47.6 240 49.4 71 57.7 50 44.2 50 36.0 42 46.7 92 40.2
Nuclear Grade < 0.001 < 0.001
Low 92 9.7 67 13.8 5 4.1 3 2.7 9 6.5 8 8.8 17 7.4
Intermediate 486 51.1 308 63.4 65 52.8 40 35.4 26 18.7 47 52.2 73 31.9
High 373 39.2 111 22.8 53 43.1 70 61.9 104 74.8 35 38.9 139 60.7
Histological Grade < 0.001 < 0.001
Well 100 10.5 63 13.0 10 8.1 11 9.7 8 5.8 8 8.9 16 7.0
Moderate 597 62.8 334 68.7 76 61.8 65 57.5 71 51.1 51 56.7 122 53.3
Poor 254 26.7 89 18.3 37 30.1 37 32.7 60 43.2 31 34.4 91 39.7
Estrogen Receptor
(ER)
< 0.001 < 0.001
Negative 364 38.3 11 2.3 11 8.9 113 100.0 139 100.0 90 100.0 229 100.0
Positive 587 61.7 475 97.7 112 91.1 0 0.0 0 0.0 0 0.0 0 0.0
Progesterone
Receptor (PR)
< 0.001 < 0.001
Negative 522 54.9 143 29.4 37 30.1 113 100.0 139 100.0 90 100.0 229 100.0
Positive 429 45.1 343 70.6 86 69.9 0 0.0 0 0.0 0 0.0 0 0.0
HER2
Negative 715 75.2 486 100.0 0 0.0 0 0.0 139 100.0 90 100.0 229 100.0
Positive 236 24.8 0 0.0 123 100.0 113 100.0 0 0.0 0 0.0 0 0.0
CK 5/6
Negative 820 86.2 474 97.7 123 100.0 103 91.2 30 21.6 90 100.0 120 52.4
Positive 131 13.8 12 2.5 0 0.0 10 8.8 109 78.4 0 0.0 109 47.6
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subtypes
51.1% (486/951) were luminal A subtype, 12.9% (123/
951) were luminal B subtype, 11.9% (113/951)) were
HER2 subtype, and 24.1% (229/951) were TN-subtype
(Table 1). Among the TN-subtype, 139 were defined as
BLBCs (14.6% (139/951)), whereas 90 cases were defined
as QNBC/5NPs 90 (9.5% (90/951)). The clinicopatholo-
gic characteristics of each breast cancer subtype are
shown in Table 1. Women with luminal A subtypes
showed lower nuclear and histologic grade. Women
with tumors of the TNBCs were younger, and less often
had lymph node involvement, but had higher nuclear
and poorer histological grades. When the TNBCs were
subdivided into BLBCs and QNBC/5NPs according to
the basal-markers, women with BLBCs maintained the
features of TNBCs, showing younger age, less often
lymph node involvement, higher nuclear and poorer his-
tological grades. 8 cases out of 10 medullary carcinomas
were assigned to BLBCs and 5 out of 6 metaplastic car-
cinomas were to TNBCs (3 in BLBCs and 2 in QNBC/
5NPs). Histologic features of representative case of
QNBC/5NPs and BLBCs are described (Additional File
1, Figure S2).
Disease free survival and overall survival by breast cancer
subtypes
DFS time ranged from 0 to 152.1 months with median
of 67.5 months. During the study period, 256 women
(26.9% (256/951)) had local recurrence and/or metasta-
sis. HR and 95% confidence intervals (95% CI) for DFS
according to breast cancer subtypes are shown in Table
2 and survival analyses were demonstrated in Figure 1A
and 1C. Advanced stage did not significantly increase
the recurrence risk of luminal B and HER2 subtype
(Table 2, Additional File 1, Figure S3). Interestingly,
BLBCs showed obvious DFS benefit with adjuvant che-
motherapy (HR, 0.24; 95% CI, 0.10-0.60; P = 0.002),
Table 1 Clinicopathologic characteristics of breast cancer subtypes (Continued)
EGFR
Negative 821 86.3 471 96.9 119 96.7 92 81.4 49 35.3 90 100.0 139 60.7
Positive 130 13.7 15 3.1 4 3.3 21 18.6 90 64.7 0 0.0 90 39.3
Histological type
Invasive ductal
carcinoma
872 91.6 438 90.1 122 99.2 106 93.8 125 89.9 81 90.0 206 90.0
Invasive lobular
carcinoma
26 2.7 22 4.5 4 4.4 4 1.7
Mucinous
carcinoma
13 1.4 10 2.1 2 1.8 1 1.1 1 0.4
Invasive papillary
carcinoma
8 0.8 5 1.0 1 0.8 2 1.4 2 0.9
Medullary
carcinoma
10 1.1 1 0.2 1 0.9 8 5.8 8 3.5
Metaplastic
carcinoma
6 0.6 1 0.2 3 2.2 2 2.2 5 2.2
Others 18 1.6 9 1.9 3 2.7
Operation
BCS 359 37.7 200 41.2 40 32.5 30 26.5 58 41.7 31 34.4 89 38.9 0.048 0.038
Mastectomy 592 62.3 286 58.8 83 67.5 83 73.5 81 58.3 59 65.6 140 61.1
Adjuvant
chemotherapy
Not done 155 16.3 95 19.5 20 16.3 22 19.5 10 7.2 8 8.9 18 7.9 0.004 0.002
Done 796 83.7 391 80.5 103 83.7 91 80.5 129 92.8 82 91.1 211 92.1
Anthracycline 292 36.7 156 39.9 40 38.8 33 36.3 34 11.6 29 35.4 63 29.9 0.101 0.114
CMF 491 61.7 229 58.6 61 59.2 58 63.7 92 71.3 51 62.2 143 67.8
Others 13 1.6 6 1.5 2 1.9 0 0 3 2.3 2 2.4 5 2.4
Radiation therapy
Not done 503 52.9 250 51.4 73 59.3 63 55.8 69 49.6 48 53.3 117 51.1 1.0 1.0
Done 448 47.1 236 48.6 50 40.7 50 44.2 70 50.4 42 46.7 112 48.9
* Five subtypes are Luminal A, Luminal B, HER2+, BLBC, and QNBC
** Four subtypes are Luminal A, Luminal B, HER2+-, and TNBC
† Chi-square test using Bonferroni’s correction
IHC: immunohistochemistry
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Page 5 of 15Table 2 Hazard ratios of breast cancer disease-free survival for several basic characteristics by breast cancer subtyping
Molecular subtyping
All Five subtypes Four subtypes
Variables (N = 951) IHC-Luminal A
(N = 486)
IHC-Luminal B
(N = 123)
IHC-HER2
(N = 113)
IHC-BLBC
(N = 139)
IHC-QNBC/5NP
(N = 90)
IHC-TNBC
(N = 229)
HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event)
(95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value
Age Group (yr)
> 50 1.00(174/590) 1.00(79/297) 1.00(32/87) 1.00(25/51) 1.00(22/97) 1.00(16/58) 1.00(38/155)
≥ 50 0.73(82/361) 0.72(38/189) 0.88(12/36) 0.42(16/62) 0.70(7/42) 1.07(10/32) 0.89(17/74)
(0.55-0.96) 0.020 (0.49-1.07) 0.856 (0.45-1.71) 1.0 (0.21-0.79) 0.056 (0.29-1.60) 1.0 (0.48-2.37) 1.0 (0.50-1.58) 1.0
Tumor size (cm)
≤ 2 cm 1.00(77/392) 1.00(38/228) 1.00(16/39) 1.00(8/35) 1.00(9/52) 1.00(6/38) 1.00(15/90)
2-5 cm 1.62(146/493) 1.86(23/75) 0.73(23/75) 1.93(25/64) 1.04(14/76) 2.72(17/47) 1.59(31/123)
(1.23-2.14) 0.001 (1.25-2.77) 0.016 (0.38-1.38) 1.0 (0.87-4.27) 0.864 (0.45-2.39) 1.0 (1.07-6.89) 0.288 (0.86-2.94) 1.0
> 5 cm 3.14(33/66) 3.32(12/27) 1.34(5/9) 2.65(7/14) 4.04(6/11) 4.67(3/5) 4.30(8/16)
(2.08-4.72) < 0.001 (.1.73-6.35) < 0.001 (0.49-3.67) 1.0 (0.96-7.30) 0.480 (1.43-11.22) 0.064 (1.16-18.22) 0.240 (1.90-9.82) 0.008
LN involvement
Negative 1.00(85/503) 1.00(31/248) 1.00(15/53) 1.00(18/64) 1.00(12/89) 1.00(9/49) 1.00(21/138)
Positive 2.54(171/448) 3.28(86/238) 1.60(29/70) 1.88(22/49) 2.75(17/50) 2.83(17/41) 2.83(34/91)
(1.96-3.30) < 0.001 (2.17-4.95) 0.001 (0.86-2.98) 0.980 (1.01-3.51) 0.376 (1.32-5.77) 0.045 (1.26-6.36) 0.096 (1.64-4.89) < 0.001
AJCC stage
I 1.00(36/254) 1.00(14/148) 1.00(8/19) 1.00(4/22) 1.00(5/38) 1.00(5/27) 1.00(10/65)
II 1.62(106/467) 2.62(50/221) 0.55(18/69) 2.02(19/57) 1.24(13/78) 0.79(6/42) 1.03(19/120)
(1.02-2.14) 0.001 (1.45-4.74) 0.008 (0.24-1.26) 1.0 (0.68-5.94) 1.0 (0.44-3.48) 1.0 (0.24-3.48) 1.0 (0.48-2.20) 1.0
III 3.14(114/230) 5.86(53/117) 1.32(18/35) 3.59(17/34) 4.31(11/23) 6.30(15/21) 5.14(26/44)
(2.08-4.72) < 0.001 (3.24-10.55) 0.001 (0.58-3.04) 1.0 (1.21-10.67) 0.176 (1.49-12.41) 0.056 (2.27-17.5) 0.001 (2.47-10.66) < 0.001
Adjuvant chemotherapy
Not done 1.00(43/155) 1.00(17/95) 1.00(9/20) 1.00(10/22) 1.00(6/10) 1.00(1/8) 1.00(7/18)
Done 0.98(213/796) 1.57(100/391) 0.63(35/103) 0.69(30/91) 0.24(23/129) 3.13(25/82) 0.59(48/211)
(0.71-1.36) 0.915 (0.94-2.64) 0.083 (0.31-1.32) 0.226 (0.34-1.42) 0.312 (0.10-0.60) 0.002 (0.43-23.2) 0.26 (0.26-1.30) 1.0
IHC: immunohistochemistry, LN: lymph node
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5whereas TNBCs did not show statistical benefit from
chemotherapy.
OS time ranged from 2.47 to 152.1 months with med-
ian of 75.0 months. During the study period, 137
women (14.4% (137/951)) died and 814 were alive at the
end of the study. HR and 95% CI for OS are shown in
Table 3 and survival analyses were demonstrated in Fig-
ure 1B and 1D. Tumor size, lymph node involvement,
and AJCC stage were significant prognostic factors in
the analysis with all cases of breast cancers but the sig-
nificance were maintained only in luminal A, TNBCs
(including BLBCs and QNBC/5NPs) after subgroup ana-
lysis with molecular subtyping. Remarkably, OS in
BLBCs and QNBC/5NPs, and TNBCs showed a dra-
matic decrease in stage III (Table 3, Additional File 1,
Figure S3). Adjuvant chemotherapy was associated with
prolonged OS in Luminal B (HR, 0.23; 95% CI, 0.09-
0.52; P = 0.007), BLBCs (HR, 0.17; 95% CI, 0.07-0.43;
P < 0.001), and TNBCs (HR, 0.41; 95% CI, 0.18-0.93;
P = 0.06).
Correlation between adjusted variables and survival
We also performed multivariate analysis for DFS and OS
including statistically significant variables (Table 4).
Although the risk of recurrence was not significant in
all cases, the HER2 and luminal B subtype was asso-
ciated with recurrence. Compared to Luminal A, all
other molecular subtypes were associated with a worse
OS. From the survival analyses with DFS and OS, HER2
subtype was the worst prognostic subtype among four-
or five subtypes (Table 4) (HR, 3.07, 95% CI, 1.86-4.87;
P < 0.001). The risk of death in women with luminal B
Figure 1 Kaplan-Meier curves of disease-free survival and overall survival. Disease-free survival according to (A) four and (C) five IHC-based
subtypes of breast cancers in the study subjects. Overall survival according to (B) four and (D) five subtypes of breast cancers in the study
subjects (Estimated mean survival with 95% CI).
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Page 7 of 15Table 3 Hazard ratios of overall survival for several basic characteristics by breast cancer subtyping
Molecular subtyping
All Five subtypes Four subtypes
Variables (N = 951) IHC-Luminal A
(N = 486)
IHC-Luminal B
(N = 123)
IHC-HER2
(N = 113)
IHC-BLBC
(N = 139)
IHC-QNBC/5NP
(N = 90)
IHC-TNBC
(N = 229)
HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event)
(95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value
Age Group (yr)
< 50 1.00(85/590) 1.00(22/297) 1.00(14/87) 1.00(21/51) 1.00(17/97) 1.00(11/58) 1.00(28/155)
≥ 50 0.99(52/361) 1.43(20/189) 1.42(8/36) 0.32(9/62) 0.92(7/42) 1.23(8/32) 1.08(15/74)
(0.70-1.39) 0.96 (0.78-2.61) 1.0 (0.59-3.37) 1.0 (0.15-0.71) 0.04 (0.38-2.20) 1.0 (0.49-3.04) 1.0 (0.58-2.03) 1.0
Tumor size (cm)
≤ 2 cm 1.00(28/392) 0.005 1.00(7/228) 1.00(5/39) 1.00(6/35) 1.00(6/52) 1.00(4/38) 1.00(10/90)
2-5 cm 2.61(87/493) 4.21(30/231) 1.29(14/75) 1.93(19/64) 1.36(12/76) 2.78(12/47) 1.86(24/123)
(1.70-4.00) < 0.001 (1.94-10.1) 0.001 (0.46-3.61) 1.0 (0.77-4.83) 1.0 (0.51-3.64) 0.65 (0.89-8.63) 0.62 (0.88-3.88) 0.010
> 5 cm 5.34(22/66) 6.55(5/27) 2.17(3/9) 2.46(5/14) 6.65(6/11) 7.76(3/5) 7.54(9/16)
(3.05-9.33) < 0.001 (2.08-20.6) 0.008 (0.51-9.16) 1.0 (0.75-8.08) 1.0 (2.13-20.3) 0.008 (1.73-34.5) 0.046 (3.12-18.2) < 0.001
LN involvement
Negative 1.00(39/498) 1.00(7/246) 1.00(7/52) 1.00(12/63) 1.00(8/89) 1.00(5/48) 1.00(13/137)
Positive 2.93(98/453) 4.88(35/240) 1.55(15/71) 2.23(18/50) 4.6(16/50) 3.96(14/42) 3.99(30/92)
(2.03-4.24) < 0.001 (2.25-10.45) < 0.001 (0.63-3.81) 1.0 (1.07-4.62) 0.26 (1.73-9.49) 0.004 (1.43-11.0) 0.064 (2.09-7.35) < 0.001
AJCC stage
I 1.00(10/254) 1.00(0/148) 1.00(2/19) 1.00(3/22) 1.00(2/38) 1.00(3/27) 1.00(5/65)
II 3.29(58/467) NA*(21/221) 1.09(10/69) 1.70(13/57) 2.74(11/78) 0.72(3/42) 1.58(14/120)
(1.68-6.43) 0.001 (0.23-5.01) 1.0 (0.48-5.97) 1.0 (0.61-12.3) 1.0 (0.14-3.58) 1.0 (0.57-4.40) 1.0
III 8.74(69/230) NA*(21/117) 2.60(10/35) 3.53(14/34) 11.36(11/23) 7.85(13/21) 9.16(24/44)
(4.50-16.9) < 0.001 (0.57-11.9) 1.0 (1.01-12.34) 0.37 (2.57-51.3) 0.016 (2.23-27.5) 0.005 (3.49-24.0) < 0.001
Adjuvant chemotherapy
Not done 1.00(35/155) 1.00(12/95) 1.00(9/20) 1.00(7/22) 1.00(6/10) 1.00(1/8) 1.00(7/18)
Done 0.59(102/796) 0.74(30/391) 0.23(13/103) 0.75(23/91) 0.17(18/129) 2.23(18/82) 0.41(36/211)
(0.40-0.87) 0.008 (0.37-1.45) 1.0 (0.09-0.52) 0.007 (0.32-1.74) 1.0 (0.07-0.43) < 0.001 (0.29-16.7) 1.0 (0.18-0.93) 0.06
* There is no event in AJCC stage I of luminal A subtype.
IHC: immunohistochemistry, LN: lymph node
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5subtypes was increased 1.86-fold (95% CI, 1.11-3.11; P =
0.018), with the BLBCs the risk was increased 2.80-fold
(95% CI, 1.68-4.68; P < 0.001), with the QNBC/5NPs
the risk was increased 3.04-fold (95% CI, 1.75-5.26; P <
0.001), and with the TNBCs the risk was increased 2.91-
fold (95% CI, 1.88-4.48; P < 0.001) compared to those
with luminal A breast cancer. The likelihood ratio test
between two Cox models was significant for DFS (P =
0.020) and OS (P = 0.016), indicating that adding model
1 (5-subgrouping) significantly improved the goodness
of fit of the model for survival analyses in breast cancer
patients. We showed that BLBC was not associated with
worse prognosis than QNBC/5NP from the multivariate
analyses for DFS and OS of TNBC patients (Table 5).
Table 4 Adjusted Hazard ratio of breast cancer survival
Model 1 (5-subgrouping) Model 2 (4-subgrouping)
Variables Disease-free survival Overall survival Disease-free survival Overall survival
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Molecular subtyping
IHC-Luminal A 1.00 1.00
IHC-Luminal B 1.48 (1.04-2.09) 0.027 1.86 (1.11-3.11) 0.018
IHC-HER2 1.60 (1.11-2.31) 0.011 3.07 (1.86-4.87) < 0.001
IHC-TNBC 1.19 (0.89-1.68) 0.293 2.91 (1.88-4.48) < 0.001
Molecular subtyping
IHC-Luminal A 1.00 1.00
IHC-Luminal B 1.48 (1.04-2.09) 0.028 1.86 (1.11-3.11) 0.018
IHC-HER2 1.60 (1.11-2.31) 0.012 3.07 (1.86-4.87) < 0.001
IHC-BLBC 1.03 (0.68-1.56) 0.874 2.80 (1.68-4.68) < 0.001
IHC-QNBC/5NP 1.43 (0.93-2.18) 0.102 3.04 (1.75-5.26) < 0.001
Tumor size (cm)
≤ 2 cm 1.00 1.00 1.00 1.00
2-5 cm 1.39 (1.06-1.86) 0.02 2.26 (1.46-3.50) < 0.001 1.39 (1.05-1.85) 0.021 2.26 (1.46-3.39) < 0.001
> 5 cm 2.19 (1.44-3.36) < 0.001 3.21 (2.13-4.67) < 0.001 2.16 (1.42-3.32) < 0.001 3.19 (1.78-5.73) < 0.001
LN involvement
Negative 1.00 1.00 1.00 1.00
Positive 2.40 (1.82-3.16) < 0.001 3.17 (2.14-4.61) < 0.001 2.41 (1.83-3.18) < 0.001 3.17 (2.14-4.61) < 0.001
Adjuvant Chemotherapy
Not done 1.00 1.00 1.00 1.00
Done 0.70 (0.50-0.99) 0.049 0.34(0.22-0.50) < 0.001 0.70 (0.50-0.99) 0.048 0.34 (0.22-0.50) < 0.001
IHC: immunohistochemistry
Table 5 Adjusted Hazard ratio of breast cancer survival in IHC-TNBC
Disease-free survival Overall survival
HR (95%CI) P-value HR (95%CI) P-value
Molecular subtyping
IHC-BLBC 1.00 1.00
IHC-QNBC/5NP 1.43 (0.84-2.45) 0.188 1.20 (0.65-2.22) 0.558
Tumor size (cm)
≤ 2 cm 1.00 1.00
2-5 cm 1.44 (0.76-2.73) 0.258 1.61 (0.75-3.46) 0.219
> 5cm 3.06 (1.27-7.35) 0.012 4.07 (1.56-10.5) 0.004
LN involvement
Negative 1.00 1.00
Positive 2.54 (1.44-4.48) 0.001 3.83 (1.92-7.65) < 0.001
Adjuvant Chemotherapy
Not done 1.00 1.00
Done 0.54 (0.23-1.28) 0.161 0.31(0.13-0.76) 0.011
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Page 9 of 15Chemotherapy effects on the subtypes
When the patients were divided into two groups
depending on the adjuvant chemotherapy, the survival
analysis revealed that patients with luminal B and
TNBCs had overall survival benefit from chemotherapy
(P < 0.001 for luminal B, P = 0.027 for TNBCs) (Figure
2). From the five-subtype analysis, the BLBCs without
adjuvant chemotherapy had a shortest DFS and OS
showing dramatic survival gain after chemotherapy (P =
0.001 for DFS, P < 0.001 for OS) (Figure 3). On the
other hand, QNBC/5NP did not show chemotherapy
benefit in both DFS and OS. However, this was difficult
to interpret due to small numbers etc (only 1 event in
the QNBC/5NP group) (Figure 3). Furthermore, multi-
variate analysis of BLBC patients for DFS and OS
including tumor size and lymph node involvement
confirmed survival gain of adjuvant chemotherapy
(Table 6). The survival gain with anthracycline-based
and non-anthracycline-based adjuvant chemotherapy did
not show statistical difference in BLBCs (data not
shown).
Molecular subtyping in public microarray datasets
In order to support our data that TNBC is substantially
different from BLBC, we explored the mRNA expression
levels of the five genes (ESR1, PGR, ERBB2, KRT5 and
EGFR) according to five subtypes in two large-sized
microarray datasets. We classified each dataset into five
subtypes from the definition of subtypes described in
Methods. From the classification, the proportion of five
subtypes in the two microarray datasets turned out to
be very similar, and it was similar to the proportion of
Figure 2 Association between chemotherapy and four-subtypes of breast cancers. Kaplan-Meier curves of disease-free survival (A and C)
and overall survival (B and D). Cases without chemotherapy (A and B) and with chemotherapy (C and D) (Estimated mean survival with 95% CI).
*P < 0.001, **P = 0.027.
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Page 10 of 15subtypes in Cheang et al.’s data set as well (Fig 4A). The
proportion of QNBC/5NP within TNBC was about 36%
and 50% in each microarray dataset, and our data set
showed similar proportion which was about 40%. The
expression patterns of each ge n ei nf i v es u b t y p e sw e r e
consistent across the datasets displaying the clear
characteristics of each subtype. Elevated expression of
KRT5 and EGFR was a distinct feature of BLBC discri-
minating it from the other subtypes, and their high
expression in BLBC were independent from the expres-
sion of other three genes - ESR1, PGR and ERBB2 -
which showed no difference between BLBC and QNBC/
Figure 3 Association between chemotherapy and five-subtypes of breast cancers. Kaplan-Meier curves of disease-free survival (A and C)
and overall survival (B and D). Cases without chemotherapy (A and B) and with chemotherapy (C and D) (Estimated mean survival with 95% CI).
*P = 0.001, **P < 0.001.
Table 6 Adjusted Hazard ratio of breast cancer survival in IHC-BLBC
Disease-free survival Overall survival
HR (95%CI) P-value HR (95%CI) P-value
Tumor size (cm)
≤ 2 cm 1.00 1.00
2-5 cm 1.49 (0.51-2.61) 0.740 1.48 (0.57-3.87) 0.422
> 5 cm 1.72 (0.55-5.32) 0.349 2.45 (0.73-8.24) 0.147
LN involvement
Negative 1.00 1.00
Positive 3.21 (1.49-6.89) 0.003 4.78 (1.95-11.73) 0.001
Adjuvant Chemotherapy
Not done 1.00 1.00
Done 0.34 (0.12-0.88) 0.028 0.22(0.08-0.59) 0.011
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Page 11 of 155NP (Figure 4B and 4C). KRT5 showed a wide range of
expression level across samples, while the expression
range of EGFR was relatively very narrow in both data-
sets, and most of the TNBC samples showing high
expression of KRT5 accompanied high expression of
EGFR (data not shown). From the overall expression
patterns of five genes, KRT5 and EGFR seemed to be
o n eo ft h em a j o rc a u s e so ft h eh e t e r o g e n e i t yo fT N B C ,
and a large portion of TNBC was non-BLBC subtypes
supporting that TNBC should not be replaced inter-
changeably with BLBC.
Discussion
In summary, with 951 breast cancer cases, we observed
that TNBCs showed a poor OS prognosis, showing
higher nuclear and/or histological grade, next to the
HER2 subtypes. The worse OS was observed in QNBC/
5NPs among TNBCs. In previous studies, the frequency
of TNBCs and BLBCs has ranged from 17.1% to 30.5%
and 8.0% to 55.7% respectively, depending upon the
definition or criteria used [21]. The difference of the fre-
quency might be explained with the method and criteria
of the IHC interpretation. In this study, the proportion
of BLBCs was 14.6% (60.7% of TNBCs), which was simi-
lar with that (14.7%) in the previous Kim et al.’s study,
which used four basal makers (CK5, CK14, EGFR,
and c-kit) [15]. We used two basal markers (CK5/6,
EGFR) in accordance with the Carolina Breast Cancer
Study [17].
When the TNBCs tumors were divided into BLBCs
and QNBC/5NPs based upon basal markers, QNBC/
5NP had the poorer OS in our study. The Luminal A
Figure 4 Comparison of the expression levels of five genes according to five subtypes in the microarray data sets. (A) Proportion of five
breast cancer subtypes in two large-sized microarray data sets. (B) Expression levels of the five markers according to the subtypes in Vijver et al.
(C) Expression levels of the five markers according to the subtypes in Wang et al. Distribution of expression levels of each marker was described
with box plots. The bottom and top of the box are the 25
th and 75
th percentile, and the band near the middle of the box is the 50th percentile.
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Page 12 of 15and BLBCs had the best DFS. Previous studies have
shown that the expression of basal markers (basal cyto-
keratins and EGFR) in TNBCs also correlates with a
worse prognosis and identifies a clinically distinct sub-
group within the TNBCs [9,10,13]. In our study, CK5/6
was a poor prognostic marker but EGFR was not (data
not shown). In Cheang et al.’s data from 3,744 cases,
17% were TNBCs and 9% were BLBCs, using the five-
marker method [13]. They showed that the poor prog-
n o s i so ft h eT N B C si sc o n f e r r e da l m o s te n t i r e l yb y
those tumors positive for basal markers, that is, BLBCs.
In our study, the clinicopathologic characteristics of
TNBCs were maintained in BLBCs after dividing into
two groups (BLBCs and QNBC/5NPs), but the poor
prognosis of the TNBCs was primarily due to the
QNBC/5NPs.
Without chemotherapy, BLBCs were worst prognostic
subtype in both DFS and OS. Interestingly, BLBCs
showed dramatic clinical ben e f i tf r o mb o t ha n t h r a c y -
cline-based and CMF adjuvant chemotherapy. On the
other hand, adjuvant chemotherapy showed little clinical
benefit for QNBC/5NP in this study. However, this
result simply reflects that some QNBC/5NP patients
may not benefit from standard chemotherapy. Several
studies of breast cancer patients treated with neoadju-
vant anthracycline-based chemotherapy have reported
higher response rates in TNBCs compared to luminal
breast cancers [22,23]. In an adjuvant setting, the HR
for relapse or death among patients with BLBCs (HR,
0.54; 95% CI, 0.27-1.08) was reduced after treatment
with anthracycline-based chemotherapy [24]. Along with
those results, our study implies that the basal markers
m a yb eu s e f u lt oi d e n t i f yT N B Cp a t i e n t sw h oa r em o s t
likely to benefit from anthracycline-containing adjuvant
chemotherapy.
The finding that QNBC/5NPs do worse with regard to
DFS and OS than BLBCs is different from the findings
by Cheang et al. [13], Carey et al. [17] and Rakha et al.
[8]. This difference might be due to the different pro-
portion of breast cancer patients with no chemotherapy
(Cheang et al: BLBCs treated/untreated: 103/179, here:
129/10). Furthermore, our results could be explained by
the fact that BLBCs have been reported to benefit from
chemotherapy [24]. Similarly the finding that BLBCs do
just as well on CMF as on anthracycline-based che-
motherapy, while QNBC/5NPs do worse on chemother-
apy contradicts with the findings of Cheang et al. This
discrepancy could be drawn from the different cohort,
especially Asian population in this study, or small
patient numbers used in this study.
Since 2001, breast cancer has been the most common
cancer in women in Korea [25]. Recently, Rhee et al.
reported that, in node-negative breast cancers, TNBC has
a higher relapse rate and more aggressive clinicopathologic
characteristics than non-TNBC [26]. However, the author
did not divide the cases into five subtypes including
BLBCs. Kim et al. reported the clinicopathologic signifi-
cance of the BLBCs based on the expression of basal cyto-
keratins [15] indicating that BLBCs were associated with
high histological and/or nuclear grades, but no statistically
significant survival differences were evident between
BLBCs and those of other subtypes. BLBCs and/or TNBCs
have been known to be associated with BRCA mutations,
which have been investigated mostly in western countries.
In the contrary, in Korea, the mutation rates of BRCA1
and 2 are extremely low, which implies that most BLBCs
or TNBCs are not associated with BRCA mutations. In the
population-based Carolina Breast Cancer Study, the preva-
lence of the BLBCs and luminal A subtypes was strongly
influenced by race and menopausal status [17]. Some dif-
ferent tumorigenic mechanism may be involved in BLBCs
or TNBCs breast cancers in Asia.
This study was limited in that the cohort is derived
from a single institution in a large city (Seoul, Korea).
Considering protein profiling by IHC is not homoge-
nous in whole sections and the results of IHC from the
TMAs usually give the lower frequencies than from the
whole sections, BLBCs by TMA-based IHC can be con-
taminated with luminal A subtypes of relatively high
proportion and their prognosis can be a little bit better
than using whole sections. To rule out this possibility,
ER and PR status were determined by assessment of
whole sections of the tumor, not from cores as in TMA,
because the patient was treated with anti-hormonal
therapy based upon the result from whole sections. The
remaining IHC results were from the TMA setting with
t w oc o p i e so f2 - m mc o r et or e p r e s e n ta b o v ea tl e a s t
98% of the whole lesion (theoretical area is 8π), since
usual one 1-mm core (theoretical area is π)r e p r e s e n t s
91% of the whole lesion and three cores (theoretical
area is 3π) do 98% [27]. In this study, positive rate of
ER and/or PR might be a little bit higher than the stu-
dies that are evaluated in TMA, implying that luminal A
or B subtypes could be more prevalent in this study.
The QNBC/5NPs was observed in about 6~8% of total
samples from publicly available breast cancer microarray
datasets, and about 40% of TNBCs were non-BLBCs,
which supports that TNBCs is not synonymous with
BLBCs. TNBCs have the poorer associated prognosis of
breast cancer subtypes, a finding which is consistent
with earlier studies. By adding EGFR and CK5/6 as basal
markers, QNBC/5NPs were found to have the worse
outcomes among TNBCs. Kreike et al. showed that,
based on the gene-expression profiling, BL-subtype
tumors (classified as TN tumors in their study) are het-
erogeneous and can be subdivided into at least five dis-
tinct subtypes [7]. Bertucci et al. called for caution in
the interpretation of ongoing trials and the selection of
Choi et al. BMC Cancer 2010, 10:507
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Page 13 of 15patients for future trials based on their data, which
showed that TNBCs represent a more heterogeneous
group than BLBCs since TNBCs include basal and non-
basal tumors, which are very different at the histological
and molecular levels, most notably in regard to mRNA
expression of molecules targeted by specific therapies
that are under evaluation in clinical trials [28]. The risk
of regarding the two tumor types as the same is that
TNBCs included in clinical trials may not be identical to
BLBCs, possibly leading to a falsely negative conclusion
of unresponsiveness to drugs that may actually be cap-
able of treating true BLBCs [28]. Bertucci et al. also
revealed that BLBCs are a more homogenous group
than TNBCs. The incomplete concordance between
BLBCs and TNBCs has been reported by using various
immunohistochemical definitions, including the ER-,
HER2-, EGFR+, and/or CK5/6+ immunohistochemical
profile, which is currently considered to be the most
reliable definition [2]. In the majority of previous stu-
dies, the basal status of many TNBCs was thought to
confer a poorer clinical outcome when compared to
non-basal TNBCs; however, our results suggest that the
QNBC/5NPs may be primarily responsible for confer-
ring poor clinical outcomes.
Conclusions
In conclusion, TNBCs and BLBCs were associated with
high histologic and/or nuclear grades. However, in con-
trast to previous data, QNBC/5NPs showed worse prog-
n o s i si nt h i ss t u d y ,w h i c hm i g h tb ef r o mt h ep o o r
response to the adjuvant chemotherapy. Based on these
findings, the prognostication and the identification of
subgroup of patients for therapeutic classification
should be re-considered with more applicable markers.
Furthermore, our study suggests that patients with
QNBC/5NP might not benefit from anthracycline-based
chemotherapy.
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